Keymed Biosciences Inc.
Keymed Biosciences Inc. (HKSE: 2162) is trading at HK$81.55, about ₹997 at today's HKD/INR rate, as of 30 Sep 2026, 4:08 AM ET, up 2.45% today. Indian residents can buy Keymed Biosciences from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$78.90
Today's high
HK$82.40
52 week low
HK$44.66
52 week high
HK$89.75
2162 opened at HK$79.50, closed previously at HK$79.60, and has traded between HK$44.66 and HK$89.75 over the past 52 weeks.
About
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
Key statistics
Avg. volume
2.70M
Market cap
HK$24.02B
P/E Ratio
25.07
Price-to-sales ratio
24.97
Enterprise value
CN¥13.40B
Free cash flow yield
-7.97%
Debt-to-equity ratio
0.17
Return on equity
-18.34%
ROIC
-14.99%
Beta
-0.15
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥697.77M
Earnings per share
-CN¥1.86
Free cash flow
-CN¥1.05B
Net profit margin
92.92%
Gross margin
68.24%
EBITDA
-CN¥489.36M
Revenue growth
62.98%
Similar securities
This is not an investment recommendation
How to buy Keymed Biosciences from India
Indian residents can buy Keymed Biosciences shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Keymed Biosciences and place an order
Find Keymed Biosciences by name or by its ticker, 2162, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Keymed Biosciences trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Keymed Biosciences position in HKD and INR. Keymed Biosciences pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Keymed Biosciences from India
Trading and taxes when buying Keymed Biosciences from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneKeymed Biosciences does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Keymed Biosciences stock?
Yes. Keymed Biosciences (2162) has been listed on the Hong Kong Stock Exchange since 2021, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Keymed Biosciences share cost in rupees?
One Keymed Biosciences share is HK$81.55 — about ₹997 at an HKD/INR rate of 12.23 on 30 Sep 2026. Both the Keymed Biosciences price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Keymed Biosciences from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Keymed Biosciences?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Keymed Biosciences shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Keymed Biosciences price. Paasa issues a capital-gains statement for your return.
Does Keymed Biosciences pay a dividend?
No. Keymed Biosciences does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Keymed Biosciences from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Keymed Biosciences a Hong Kong SAR China company, and does that change how it is taxed?
Keymed Biosciences trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Keymed Biosciences trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Keymed Biosciences shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Keymed Biosciences holding, its cost and its closing value.
How do I sell Keymed Biosciences and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.